mCRPC Care: Reducing Progression Risk by Combining Enzalutamide and Talazoparib

Dive into the findings from the TALAPRO-2 trial, which examined a combination regimen for metastatic castration-resistant prostate cancer.

ReachMD Healthcare Image
Media formats available
  • Completing the pre-test is required to access this content.
    Pre-Survey
    Completing the pre-survey is required to access this content.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free